Clinton health plan opposed by biotech health organization
In a statement, Jim Greenwood, president of the Biotechnology Industry Organization, said Clinton’s proposal would include added regulations that would ultimately hamper patient access to innovative new cures and therapies.
“The proposal released today by the Clinton campaign would do irreparable harm to the nation’s health innovation system, significantly hindering the ability of emerging biotechnology companies to develop the new cures and therapies that patients need to live longer, more productive lives," Greenwood said. "Intrusive government regulation of a system that relies on entrepreneurial vision and private capital is a recipe for failure.
Greenwood said similar provisions of the Clinton plan have been debated in the past and voted down on a bipartisan basis.
"We believe that fewer medicines would be produced and patient access to those medicines would be limited if the government set prices and became involved in private sector research and development,” Greenwood said.